News
EMBC
10.87
+3.77%
0.40
3 Healthcare Stocks Paying the Highest Dividends of 2026
The Motley Fool · 8h ago
Embecta: Stable Execution, GLP-1–Driven Growth Optionality, and Attractive Valuation Support Buy Rating and $25 Target
TipRanks · 18h ago
Embecta Price Target Maintained With a $25.00/Share by BTIG
Dow Jones · 18h ago
BTIG Reiterates Buy on Embecta, Maintains $25 Price Target
Benzinga · 18h ago
Embecta (EMBC) Margin Rebound And 4.4x P E Challenge Cautious Narratives
Simply Wall St · 1d ago
Embecta outlines $1.71B–$1.93B revenue target for 2026 as GLP-1 partnerships gain traction
Seeking Alpha · 1d ago
Embecta (EMBC) Q1 2026 Earnings Call Transcript
The Motley Fool · 1d ago
Embecta meldet Forschungs- und Entwicklungsausgaben im ersten Quartal 2026 von 4,6 Mio. USD, ein Rückgang um 77 Prozent
Reuters · 1d ago
Embecta Non-GAAP EPS of $0.71, revenue of $261.2M
Seeking Alpha · 1d ago
Embecta reports Q1 adjusted EPS 71c, consensus 67c
TipRanks · 1d ago
Embecta backs FY26 adjusted EPS view $2.80-$3.00, consensus $2.89
TipRanks · 1d ago
*Embecta Backs FY26 Adj EPS $2.80-Adj EPS $3.00 >EMBC
Dow Jones · 1d ago
*Embecta Backs FY26 Rev $1.07B-$1.09B >EMBC
Dow Jones · 1d ago
*Embecta 1Q Adj EPS 71c >EMBC
Dow Jones · 1d ago
*Embecta 1Q Rev $261.2M >EMBC
Dow Jones · 1d ago
*Embecta 1Q EPS 74c >EMBC
Dow Jones · 1d ago
EMBECTA Q1 ADJUSTED EPS USD 0.71
Reuters · 1d ago
Embecta Affirms FY2026 Adj EPS Guidance of $2.80-$3.00 vs $2.91 Est; Affirms FY2026 Sales Guidance of $1.071B-$1.093B vs $1.080B Est
Benzinga · 1d ago
Embecta Corporation veröffentlicht Finanzbericht für das erste Quartal 2026
Reuters · 1d ago
Embecta Corporation Announces First Quarter Fiscal 2026 Financial Results Release
Reuters · 1d ago
More
Webull provides a variety of real-time EMBC stock news. You can receive the latest news about Embecta Corp through multiple platforms. This information may help you make smarter investment decisions.
About EMBC
Embecta Corp. is a global diabetes care company. It is focused on providing solutions to people living with diabetes. It has a portfolio of products, including a range of pen needles, syringes and safety injection devices, which are complemented by its digital application designed to assist people with managing their diabetes. Its pen needles are sterile, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. In addition to pen needles, it sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It has clearance from the FDA for its proprietary disposable insulin delivery system, which is indicated for adults who require insulin to manage diabetes, including both type 1 (T1D) and type 2 (T2D).